Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations.

导出 OA

翻译打印收藏纠错

作者： Jia-Li,Wang ^[1] ; Chuan-Sheng,Chen ^[2] ; Zhi-Rong,Jia ^[1] ; Li-Yun,Miao ^[3] ; Jun,Xie ^[4] ; Zhen-Zhen,Pan ^[1] ; Ya-Lei,Duan ^[1] ; Shuo,Liu ^[1] ; Meng-Jun,Hou ^[1] ; Xuan-Sheng,Ding ^[5]

作者单位： School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. ^[1] Nanjing Medical University, Nanjing, 211166, China. ^[2] The Affiliated Drum Tower Hospital of Nanjing University Medical College, Nanjing, 210008, China. ^[3] The Affiliated Cancer Hospital of Anhui University of Science and Technology, Huainan, 232033, China. ^[4] School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. 1020030749@cpu.edu.cn. ^[5]

关键词 EGFR-TKIs Non-small cell lung cancer Progression free survival Shenqi Fuzheng injection

主题词人类(Humans);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);肺肿瘤(Lung Neoplasms);回顾性研究(Retrospective Studies);蛋白激酶抑制剂(Protein Kinase Inhibitors);突变(Mutation)

DOI 10.1007/s00432-022-04297-3

PMID 36008690

发布时间 2023-07-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交